Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 320-326

  Peddi, Parvin F ^a,b   Shatsky, Rebecca A ^a,b   Hurvitz, Sara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Breast cancer; Cough; Dyspnea; Everolimus; MTOR inhibitors; Noninfectious pneumonitis

Indexed keywords

CARBOPLATIN; DOCETAXEL; EVEROLIMUS; EXEMESTANE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METHYLPREDNISOLONE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PREDNISONE; PROTEIN KINASE B; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BREAST CANCER; BREAST METASTASIS; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG BIOPSY; LUNG LAVAGE; METASTASIS; NAUSEA; NONINFECTIOUS PNEUMONITIS; OVERALL SURVIVAL; OXYGEN THERAPY; PERIPHERAL EDEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BREAST CANCER; COUGH; DYSPNEA; EVEROLIMUS; MTOR INHIBITORS; NONINFECTIOUS PNEUMONITIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COUGH; DYSPNEA; ELAFIN; FEMALE; HUMANS; INCIDENCE; PNEUMONIA; PROTO-ONCOGENE PROTEINS C-AKT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84888297088     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.08.004     Document Type: Review

References (44)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166.
2. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366(6):520-529. 10.1056/NEJMoa1109653.
3. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8(8):627-644. 10.1038/nrd2926.
4. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124(3):471-484. 10.1016/j.cell.2006.01.016.
5. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945. 10.1101/gad.1212704.
6. Laplante M., Sabatini D.M. MTOR signaling in growth control and disease. Cell 2012, 149(2):274-293. 10.1016/j.cell.2012.03.017.
7. Lauring J., Park B.H., Wolff A.C. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw 2013, 11(6):670-678.
8. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
9. Yamnik R.L., Holz M.K. MTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010, 584(1):124-128. 10.1016/j.febslet.2009.11.041.
10. Yamnik R.L., Digilova A., Davis D.C., Brodt Z.N., Murphy C.J., Holz M.K. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009, 284(10):6361-6369. 10.1074/jbc.M807532200.
11. Miller T.W., Hennessy B.T., González-Angulo A.M., et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120(7):2406-2413. 10.1172/JCI41680.
12. de Graffenried L.A., Friedrichs W.E., Russell D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004, 10(23):8059-8067. 10.1158/1078-0432.CCR-04-0035.
13. Boulay A., Rudloff J., Ye J., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005, 11(14):5319-5328. 10.1158/1078-0432.CCR-04-2402.
14. Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402. 10.1016/j.ccr.2007.08.030.
15. O'Brien N.A., Browne B.C., Chow L., et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9(6):1489-1502.
16. Jegg A.-M., Ward T.M., Iorns E., et al. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 2012, 136(3):683-692. 10.1007/s10549-012-2252-9.
17. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64(1):36-42.
18. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281. 10.1056/NEJMoa066838.
19. Wolff A.C., Lazar A.A., Bondarenko I., et al. Randomized phase III Placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013, 31(2):195-202. 10.1200/JCO.2011.38.3331.
20. Pham P.-T.T., Pham P.-C.T., Danovitch G.M., et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004, 77(8):1215-1220.
21. Barber N.A., Ganti A.K. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011, 6(4):235-243. 10.1007/s11523-011-0199-0.
22. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182(3):396-403. 10.1164/rccm.200911-1720OC.
23. Albiges L., Chamming's F., Duclos B., et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012, 23(8):1943-1953. 10.1093/annonc/mds115.
24. Duran I., Siu L.L., Oza A.M., et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42(12):1875-1880. 10.1016/j.ejca.2006.03.015.
25. Sarkaria J.N., Galanis E., Wu W., et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 2010, 16(22):5573-5580. 10.1158/1078-0432.CCR-10-1453.
26. Dabydeen D.A., Jagannathan J.P., Ramaiya N., et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012, 48(10):1519-1524. 10.1016/j.ejca.2012.03.012.
27. Chhajed P.N., Dickenmann M., Bubendorf L., Mayr M., Steiger J., Tamm M. Patterns of pulmonary complications associated with sirolimus. Respiration 2006, 73(3):367-374. 10.1159/000087945.
28. Iacovelli R., Palazzo A., Mezi S., Morano F., Naso G., Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012, 51(7):873-879. 10.3109/0284186X.2012.705019.
29. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(16):2630-2637. 10.1200/JCO.2008.18.8391.
30. Rugo H, Gnant M, Gebert M, Csoszi T, Feng W, Bauly H. Everolimus-related adverse events: safety insights from BOLERO-2. Abstract 274. Poster Presented at St. Gallen International Breast Cancer Conference, St. Gallen, Switzerland; 2013, March 13-16.
31. Yoshinori I, Noguchi S, Deleu I, Baselga J, Hortobagyi G, Bachelot T. Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. J Clin Oncol 31, 2013 (suppl.; abstr 561) [accessed 23.07.2013]. Available at: http://www.meetinglibrary.asco.org/content/112409-132.
32. Ellard S.L., Clemons M., Gelmon K.A., et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27(27):4536-4541. 10.1200/JCO.2008.21.3033.
33. Schwarzlose-Schwarck S., Scholz C.W., Regierer A.C., et al. The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer-a phase I trial. Anticancer Res 2012, 32(8):3435-3441.
34. Moulder S., Gladish G., Ensor J., et al. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 2012, 118(9):2378-2384. 10.1002/cncr.26571.
35. Morrow P.K., Wulf G.M., Ensor J., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29(23):3126-3132. 10.1200/JCO.2010.32.2321.
36. Jerusalem G., Fasolo A., Dieras V., et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011, 125(2):447-455. 10.1007/s10549-010-1260-x.
37. Andre F., Campone M., O'Regan R., et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010, 28(34):5110-5115. 10.1200/JCO.2009.27.8549.
38. Dimopoulou I., Bamias A., Lyberopoulos P., Dimopoulos M.A. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006, 17(3):372-379. 10.1093/annonc/mdj057.
39. O'Regan R., Ozguroglu M., Andre F., Toi M., Wilks S., Isaacs C. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 2013, 31.
40. Morelon E., Stern M., Israël-Biet D., et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001, 72(5):787-790.
41. Schmitz F., Heit A., Dreher S., et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008, 38(11):2981-2992. 10.1002/eji.200838761.
42. Weichhart T., Costantino G., Poglitsch M., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29(4):565-577. 10.1016/j.immuni.2008.08.012.
43. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30(22):2718-2724. 10.1200/JCO.2011.39.0708.
44. Novartis Pharmaceuticals Corporation. Afinitor (everolimus) tablets for oral administration; 2012.